Strolll secures €5 million in Innovate UK debt and grant funding
What's the deal? Strolll, a Stafford-based software-as-a-medical-device company, has secured €5 million (£4.3 million) in separate Innovate UK funding: a €4.18 million (£3.6 million) innovation loan and an €813.2k (£700,000) Growth Catalyst Investor Partnerships (GCIP) award.
The breakdown: The innovation loan is debt funding for StrolllAssessment, while the GCIP award is a grant for StrolllAcute. The two awards fund distinct projects and are not a Series A or other equity round. The article also reports a separate investment led by IW CapitalDealroom has a profile for this one. Try Dealroom →, with participation from Cleveland Clinic and Future Planet Capital RegionalDealroom has a profile for this one. Try Dealroom →, but does not disclose its amount.
What's the endgame? Founded in 2018, Strolll builds digital therapeutics delivered through augmented reality glasses for patients with neurological disorders, in both clinics and homes. The Innovate UK funding supports two products: StrolllAssessment, an AI biomechanics lab, and StrolllAcute, a bedside AR system for bed-bound patients.
Why now? Strolll says the neurorehabilitation market is growing as more people need access to rehabilitation and ongoing support. The company aims to make therapy more engaging and easier to access.
The details: The innovation loan will establish a fully equipped biomechanics lab in Stafford to validate multiple digital assessments at once, potentially cutting a years-long process to months. The GCIP award supports StrolllAcute, which enables early intervention without adding staff burden.
Chief executive officer and co-founder Jorgen Ellis said the funding will help "increase patient engagement, support progression and help clinicians deliver effective neurorehabilitation to a wider patient population."
Scott O'Brien, chief investment officer at Innovate UK, said Strolll won backing because "it has proven both its technical excellence and a credible route to commercial success."
The signal: Strolll is combining government-backed debt and grant funding to advance clinical validation and an acute-care product, while pursuing separate private investment. That mix can help a medtech company fund lengthy validation work without treating non-dilutive support as equity.
Read more: EU-Startups
Image credit: Generated with Gemini
